PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MRNA vs. XLV
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between MRNA and XLV is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

MRNA vs. XLV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and Health Care Select Sector SPDR Fund (XLV). The values are adjusted to include any dividend payments, if applicable.

100.00%200.00%300.00%400.00%500.00%600.00%JulyAugustSeptemberOctoberNovemberDecember
106.24%
67.96%
MRNA
XLV

Key characteristics

Sharpe Ratio

MRNA:

-0.90

XLV:

0.35

Sortino Ratio

MRNA:

-1.37

XLV:

0.54

Omega Ratio

MRNA:

0.83

XLV:

1.07

Calmar Ratio

MRNA:

-0.60

XLV:

0.31

Martin Ratio

MRNA:

-1.32

XLV:

1.06

Ulcer Index

MRNA:

41.81%

XLV:

3.57%

Daily Std Dev

MRNA:

60.97%

XLV:

10.92%

Max Drawdown

MRNA:

-92.39%

XLV:

-39.17%

Current Drawdown

MRNA:

-92.08%

XLV:

-12.34%

Returns By Period

In the year-to-date period, MRNA achieves a -61.43% return, which is significantly lower than XLV's 1.83% return.


MRNA

YTD

-61.43%

1M

-2.91%

6M

-71.22%

1Y

-56.94%

5Y*

14.15%

10Y*

N/A

XLV

YTD

1.83%

1M

-3.25%

6M

-5.17%

1Y

3.11%

5Y*

7.75%

10Y*

8.63%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MRNA vs. XLV - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Health Care Select Sector SPDR Fund (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MRNA, currently valued at -0.90, compared to the broader market-4.00-2.000.002.00-0.900.35
The chart of Sortino ratio for MRNA, currently valued at -1.37, compared to the broader market-4.00-2.000.002.004.00-1.370.54
The chart of Omega ratio for MRNA, currently valued at 0.83, compared to the broader market0.501.001.502.000.831.07
The chart of Calmar ratio for MRNA, currently valued at -0.60, compared to the broader market0.002.004.006.00-0.600.31
The chart of Martin ratio for MRNA, currently valued at -1.32, compared to the broader market0.0010.0020.00-1.321.06
MRNA
XLV

The current MRNA Sharpe Ratio is -0.90, which is lower than the XLV Sharpe Ratio of 0.35. The chart below compares the historical Sharpe Ratios of MRNA and XLV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.002.50JulyAugustSeptemberOctoberNovemberDecember
-0.90
0.35
MRNA
XLV

Dividends

MRNA vs. XLV - Dividend Comparison

MRNA has not paid dividends to shareholders, while XLV's dividend yield for the trailing twelve months is around 1.22%.


TTM20232022202120202019201820172016201520142013
MRNA
Moderna, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XLV
Health Care Select Sector SPDR Fund
1.22%1.59%1.47%1.33%1.49%2.17%1.58%1.47%1.60%1.43%1.35%1.52%

Drawdowns

MRNA vs. XLV - Drawdown Comparison

The maximum MRNA drawdown since its inception was -92.39%, which is greater than XLV's maximum drawdown of -39.17%. Use the drawdown chart below to compare losses from any high point for MRNA and XLV. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-92.08%
-12.34%
MRNA
XLV

Volatility

MRNA vs. XLV - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 19.57% compared to Health Care Select Sector SPDR Fund (XLV) at 3.39%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%JulyAugustSeptemberOctoberNovemberDecember
19.57%
3.39%
MRNA
XLV
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab